Valbiotis SA (ALVAL.PA)
EUR 1.36
(-1.59%)
EUR 1.36
(-1.59%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -7.16 Million EUR | 34.14% |
| 2022 | -14.05 Million EUR | -29.29% |
| 2021 | -10.87 Million EUR | -100.79% |
| 2020 | -5.41 Million EUR | 22.42% |
| 2019 | -6.97 Million EUR | -45.76% |
| 2018 | -4.78 Million EUR | -99.42% |
| 2017 | -2.4 Million EUR | -319.76% |
| 2016 | -572 Thousand EUR | 40.1% |
| 2015 | -955 Thousand EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -3.71 Million EUR | 0.0% |
| 2023 Q4 | -5.36 Million EUR | 0.0% |
| 2023 FY | -9.25 Million EUR | 34.14% |
| 2023 Q2 | -1.8 Million EUR | 0.0% |
| 2022 Q4 | -8.24 Million EUR | 0.0% |
| 2022 FY | -14.05 Million EUR | -29.29% |
| 2022 Q2 | -5.8 Million EUR | 0.0% |
| 2021 FY | -10.87 Million EUR | -100.79% |
| 2021 Q2 | -3.98 Million EUR | 0.0% |
| 2021 Q4 | -6.88 Million EUR | 0.0% |
| 2020 Q4 | -2.26 Million EUR | 0.0% |
| 2020 FY | -5.41 Million EUR | 22.42% |
| 2020 Q2 | -3.15 Million EUR | 0.0% |
| 2019 FY | -6.97 Million EUR | -45.76% |
| 2019 Q4 | -3.36 Million EUR | 0.0% |
| 2019 Q2 | -3.61 Million EUR | 0.0% |
| 2018 FY | -4.78 Million EUR | -99.42% |
| 2018 Q4 | -2.87 Million EUR | 0.0% |
| 2018 Q2 | -1.91 Million EUR | 0.0% |
| 2017 Q4 | -2.06 Million EUR | 0.0% |
| 2017 FY | -2.4 Million EUR | -319.76% |
| 2017 Q2 | -335 Thousand EUR | 0.0% |
| 2016 Q1 | -142.5 Thousand EUR | 0.0% |
| 2016 FY | -572 Thousand EUR | 40.1% |
| 2016 Q4 | -397 Thousand EUR | 0.0% |
| 2016 Q2 | -180 Thousand EUR | -26.32% |
| 2015 Q4 | -142.5 Thousand EUR | 0.0% |
| 2015 FY | -955 Thousand EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -109.848% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 94.379% |
| Adocia SA | -17.62 Million EUR | 59.369% |
| Aelis Farma SA | -6.46 Million EUR | -10.819% |
| Biophytis S.A. | -14.33 Million EUR | 50.045% |
| Advicenne S.A. | -6.45 Million EUR | -10.887% |
| genOway Société anonyme | 2.06 Million EUR | 446.682% |
| IntegraGen SA | -183.77 Thousand EUR | -3796.175% |
| Medesis Pharma S.A. | -4.22 Million EUR | -69.294% |
| Neovacs S.A. | -6.9 Million EUR | -3.655% |
| NFL Biosciences SA | -4.43 Million EUR | -61.61% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -820.028% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -128.225% |
| Sensorion SA | -22.31 Million EUR | 67.908% |
| Theranexus Société Anonyme | -7.64 Million EUR | 6.328% |
| TME Pharma N.V. | -5.62 Million EUR | -27.312% |
| TheraVet SA | -2.17 Million EUR | -229.179% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 64.708% |
| argenx SE | -417.15 Million EUR | 98.284% |
| BioSenic S.A. | -7.04 Million EUR | -1.705% |
| Celyad Oncology SA | -8.45 Million EUR | 15.336% |
| DBV Technologies S.A. | -85.24 Million EUR | 91.601% |
| Galapagos NV | -88.26 Million EUR | 91.888% |
| Genfit S.A. | -26.58 Million EUR | 73.062% |
| GeNeuro SA | -14.35 Million EUR | 50.13% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 55.23% |
| Innate Pharma S.A. | -12.66 Million EUR | 43.484% |
| Inventiva S.A. | -102.7 Million EUR | 93.029% |
| MaaT Pharma SA | -19.94 Million EUR | 64.098% |
| MedinCell S.A. | -20.97 Million EUR | 65.867% |
| Nanobiotix S.A. | -26.77 Million EUR | 73.263% |
| Onward Medical N.V. | -35.46 Million EUR | 79.81% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -57.391% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 68.851% |
| Oxurion NV | -12.11 Million EUR | 40.875% |
| Pharming Group N.V. | -4.87 Million EUR | -46.735% |
| Poxel S.A. | -28.76 Million EUR | 75.108% |
| GenSight Biologics S.A. | -29.69 Million EUR | 75.889% |
| Transgene SA | -30.01 Million EUR | 76.143% |
| Financière de Tubize SA | -2.14 Million EUR | -233.959% |
| UCB SA | 604 Million EUR | 101.185% |
| Valneva SE | -82.08 Million EUR | 91.278% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 75.171% |